Compare DSWL & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSWL | BTMD |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | Macau | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.4M | 39.0M |
| IPO Year | 2000 | 2021 |
| Metric | DSWL | BTMD |
|---|---|---|
| Price | $2.88 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $2.61 |
| AVG Volume (30 Days) | 5.5K | ★ 99.9K |
| Earning Date | 11-16-2026 | 11-04-2026 |
| Dividend Yield | ★ 7.02% | N/A |
| EPS Growth | N/A | ★ 722.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $192,219,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.45 |
| P/E Ratio | $4.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.80 | $1.00 |
| 52 Week High | $4.06 | $2.98 |
| Indicator | DSWL | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 32.51 | 48.84 |
| Support Level | N/A | $1.01 |
| Resistance Level | $3.48 | $1.68 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 5.02 | 62.36 |
Deswell Industries Inc comprise the manufacturing and sales of injection-molded plastic parts and components and electronic products assembling. The manufacturing activities are subcontracted to operating in the Macao Special Administrative Region (Macao) of the PRC. It produce a wide variety of plastic parts and components that are used in the manufacture of consumer and industrial products, using different plastic injection technologies, such as film injection, integrated injection and insert injection. It has two segments: plastic injection molding and electronic products assembling. It has generates majority of profit from Electronic Segment. It has presence in China, United States, Europe, Hong Kong, United Kingdom, Canada, and Others of which majority of sales is from China.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.